BROOMFIELD, Colo., Aug. 1 /PRNewswire/ — ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that it has appointed James Carr, PharmD, as vice president of marketing. In this newly created position, Mr. Carr will define and execute marketing programs to support the company’s lead product candidate, Gencaro(TM) (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator in late-stage development for heart failure.
“Jim brings senior pharmaceutical industry experience and a deep knowledge of the heart failure market, which will be of significant value to ARCA as the company prepares to commercialize the first personalized cardiovascular medicine,” said Richard B. Brewer, president and chief executive officer of ARCA. “We are pleased to be able to attract talented professionals to help us accelerate the company’s growth and success, and welcome Jim to the ARCA team.”
Mr. Carr joins ARCA from Anesiva, Inc., where he served as vice president of marketing for pain management products since 2004. In this role, he was responsible for leading the development and launch teams for Zingo(TM), a rapid acting topical anesthetic. Prior to Anesiva, Mr. Carr was with GlaxoSmithKline (GSK) for eight years, where he led the launch for the post-myocardial infarction indication for Coreg(R) (carvedilol), a leading treatment for heart failure. During his tenure at GSK, Carr held management positions in professional relations, managed care marketing, medical education, advisory boards, publications, and lifecycle management.
Prior to joining the pharmaceutical industry, Mr. Carr was a researcher at the University at Buffalo School of Pharmacy. He earned a Doctor of Pharmacy degree from the University of Minnesota and conducted post-graduate work in the area of polymorphic drug metabolism of beta-blockers, also at the University of Minnesota.
About ARCA biopharma
ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company’s lead product, Gencaro(TM) (bucindolol hydrochloride), is a pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that predict individual patient response to Gencaro. The company plans to file a New Drug Application with the U.S. Food and Drug Administration during the summer of 2008 for approval of Gencaro for the treatment of heart failure. The companion genetic test for Gencaro is in development by ARCA’s partner, Laboratory Corporation of America. If approved, Gencaro could become the first genetically personalized cardiovascular therapy. For more information please visit http://www.arcabiopharma.com/.
ARCA biopharma, Inc.
CONTACT: Rebekah Brooks of Invigorate, +1-312-284-4707, cell,+1-312-286-7134, [email protected], for ARCA biopharma, Inc.
Web site: http://www.arcabiopharma.com/
Comments